AYGEN, B. Et Al. 2019. Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experienc. AASLD - TASL CONNECT REGIONAL MEETING , (İstanbul, Turkey).

AYGEN, B., DEMİRTÜRK, N., YILDIZ, O., ÇELEN, M. K., ÇELİK, İ., BARUT, H. Ş., ... BATIREL, A.(2019). Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experienc . AASLD - TASL CONNECT REGIONAL MEETING, İstanbul, Turkey

AYGEN, BİLGEHAN Et Al. "Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experienc," AASLD - TASL CONNECT REGIONAL MEETING, İstanbul, Turkey, 2019

AYGEN, BİLGEHAN Et Al. "Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experienc." AASLD - TASL CONNECT REGIONAL MEETING , İstanbul, Turkey, 2019

AYGEN, B. Et Al. (2019) . "Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experienc." AASLD - TASL CONNECT REGIONAL MEETING , İstanbul, Turkey.

@conferencepaper{conferencepaper, author={BİLGEHAN AYGEN Et Al. }, title={Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experienc}, congress name={AASLD - TASL CONNECT REGIONAL MEETING}, city={İstanbul}, country={Turkey}, year={2019}}